Related Experiment Video

Updated: Jun 23, 2026

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels

Taflan Salepci1, Mesut Seker, Huseyin Uyarel

  • 1Department of Medical Oncology, Dr Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey.

Medical Oncology (Northwood, London, England)
|May 6, 2009
PubMed

Insights

This study found that 5-Fluorouracil (5-FU) did not significantly alter angiotensin II levels, suggesting ACE inhibitors may not prevent 5-FU cardiotoxicity. Further research is needed to understand the multifactorial mechanisms of 5-FU-induced cardiac damage.

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • The mechanisms underlying 5-Fluorouracil (5-FU) cardiotoxicity remain unclear, limiting the development of prophylactic strategies.
  • Angiotensin converting enzyme (ACE) inhibitors have not been previously investigated for preventing 5-FU-associated cardiotoxicity.

Purpose of the Study:

  • To investigate the impact of 5-FU administration on brachial artery diameter and angiotensin II levels.
  • To assess the potential role of angiotensin II in 5-FU-induced cardiotoxicity and vasoconstriction.

Main Methods:

  • A study group received bolus 5-FU/leucovorin, while a control group did not.
  • Measurements included brachial artery diameter, angiotensin II levels, troponin T, and blood/organ function tests.
  • Serial blood samples were collected before, during, and up to 72 hours after treatment.

Main Results:

  • 5-FU treatment caused a statistically significant decrease in brachial artery diameter (P = 0.001), unlike in the control group (P = 0.979).
  • Angiotensin II levels did not change significantly during serial measurements (P = 0.496) and were not different between groups (P = 0.372).
  • The observed vasoconstriction associated with 5-FU was independent of angiotensin II levels.

Conclusions:

  • 5-FU-induced vasoconstriction is not mediated by angiotensin II.
  • Prophylactic use of ACE inhibitors is unlikely to prevent 5-FU cardiotoxicity.
  • The cardiotoxic effects of 5-FU are likely multifactorial, requiring further investigation into its impact on coronary endothelium and myocardium.

More Related Videos

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...